Thorne is selling supplements’ future.
What’s happening: According to FT, CPG giant Unilever is among several bidders for the supplement maker, with a potential deal valuing the company at ~$4B.
Upsizing. Originally founded as a practitioner-recommended brand, Thorne evolved for DTC, using clinical positioning to convey premium quality.
After being acquired by L Catterton for $680M in 2023, it has seen ~30% annual growth, surpassing $500M in revenue last year and expecting to reach ~$650M in 2026.
Daily double. Aiming to bring transparency to an unregulated market, Thorne is winning with discerning consumers, particularly younger crowds. ~60% of Thorne’s revenue is from under-40s, and half of those maintain regular subscriptions.
Buy-in. If successful, the move would extend Unilever’s push into wellness — adding to a portfolio that includes OLLY, Liquid I.V., Nutrafol, and Grüns.
As insurgent brands outpace incumbent CPG, Unilever and other conglomerates are leaning into faster-growing beauty and well-being categories.
Takeaway: A hefty price tag, if the deal proceeds, it’s the latest signal that consumers and their suppliers are willing to pay up for trustworthy, science-backed wellness brands.
